Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	308.08	276.98	178.96	170.28	185.31	154.34
Revenue Growth	50.13%	54.77%	5.10%	-8.11%	20.06%	56.88%
Gross Profit Gross Profit Growth	144.62	111.85	3.92	-27.39	-14.36	-37.3
Operating Income Operating Income Growth	-37.46	-57.12	-155.34	-201.61	-200.19	-208.97
Net Income Net Income Growth	-63.85	-59.5	-159.49	-225.25	-200.19	-207.28
Earnings Per Share EPS Growth	-0.41	-0.39	-1.08	-1.56	-1.40	-1.48
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Minimal Residual Disease (MRD) Minimal Residual Disease (MRD) Growth	251.94	212.33	145.53	102.74	87.14
Immune Medicine Immune Medicine Growth	56.15	64.64	33.43	67.54	98.16
Total Total Growth	308.08	276.98	178.96	170.28	185.31

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	371.74	240.21	255.95	346.4	498.2	570.21
Total Debt Total Debt Growth	410.5	210.36	222.67	229.43	233.36	111.74
Net Cash (Debt) Net Cash Growth	-38.76	29.86	33.29	116.97	264.83	458.47
Net Cash Growth	-	-10.30%	-71.54%	-55.83%	-42.23%	-34.41%
Net Cash Per Share Net Cash Per Share Growth	-0.25	0.20	0.23	0.81	1.86	3.27

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-21.01	-45.99	-95.21	-156.32	-183.95	-192.73
Capital Expenditures CapEx Growth	-3.03	-2.96	-3.66	-10.7	-16.35	-61.75
Free Cash Flow Free Cash Flow Growth	-24.03	-48.95	-98.88	-167.02	-200.29	-254.47
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	46.94%	40.38%	2.19%	-16.09%	-7.75%	-24.17%
Operating Margin	-12.16%	-20.62%	-86.80%	-118.40%	-108.03%	-135.39%
Pretax Margin	-20.77%	-21.47%	-89.18%	-132.32%	-108.13%	-134.31%
Profit Margin	-20.73%	-21.48%	-89.12%	-132.28%	-108.03%	-134.30%
FCF Margin	-7.80%	-17.67%	-55.25%	-98.09%	-108.09%	-164.87%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PS Ratio	12.44	8.95	4.94	4.17	5.90	25.66

Data Source: S&P Global Market Intelligence Last updated: Aug 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error